Robbins LLP announced a class action lawsuit against The Chemours Company, alleging overstated demand for Opteon products led to unreliable fiscal 2026 guidance. Following reduced EBITDA guidance, Che
Goldman Sachs lowered Chemours' price target to $16 from $17, maintaining a Neutral rating based on 2027 earnings estimates. The chemical manufacturer's stock has declined 36% over six months despite
Chemours exceeded responsible procurement targets, with 84% of suppliers improving sustainability performance. The company integrates carbon data into procurement decisions to reduce upstream emission
Chemours shares gained 1.31% to $13.89 despite UBS lowering its price target to $16, while Q2 revenue reached $1.591 billion with a narrowed net loss. Analyst consensus remains Hold with an average 12
Environmental groups accuse Chemours of failing to meet 2019 PFAS discharge reduction targets at its Fayetteville plant, highlighting ongoing pollution concerns despite a $600 million settlement and p
Environmental groups allege Chemours violated a 2019 consent order by failing to adequately reduce PFAS discharges from its Fayetteville Works plant. Chemours disputes these claims despite a recent $6
Chemours and other chemical firms face accusations of evading accountability for global PFAS contamination by shifting production and waste. The report criticizes lax regulations and corporate lobbyin
This report provides financial actuals and estimates for Chemours Co. on the Hannover Stock Exchange, covering valuation metrics, analyst forecasts, earnings, and revenue data.
The Village of Bald Head Island secured a $5.7 million settlement from Chemours and partners for PFAS contamination in the Cape Fear River, funding remediation and infrastructure upgrades through 2035
Mizuho maintained its Outperform rating for Chemours but lowered the price target to $18 due to market challenges, noting the stock remains moderately undervalued.
Chemours Co. disclosed cash flow data for 2025 and Q2 2026, recording €224.77 million in operating cash flow for 2025. The report covers historical investing and financing activities listed on the Han
Chemours Co. (2CU) financial data and stock performance are displayed on the Hannover Stock Exchange, including market cap, dividend yield, and analyst ratings.
Options traders are showing significant interest in Chemours stock with high implied volatility, despite a Zacks Sell rating and lowered earnings estimates indicating potential price movement.
Chemours introduces advanced liquid-cooling solutions, including two-phase direct-to-chip and immersion cooling, to enhance energy efficiency and reduce water usage in AI data centers.
Environmental groups allege Chemours violated a 2019 consent order by discharging PFAS into the Cape Fear River, though the company denies the claims and cites mitigation efforts. Legal action may fol
Environmental groups sent a warning letter to Chemours alleging its Fayetteville Works facility violated a 2019 consent order by discharging high PFAS levels without adequate groundwater remediation.
Wood County residents filed a class-action lawsuit against Chemours alleging PFAS contamination from its Washington Works plant damaged homes and land. Plaintiffs seek cleanup, compensation, and medic
Chemours Co shares rose after reaching a multi-party settlement regarding PFAS emissions at its Fayetteville Works facility. Despite the gain, analysts note the stock remains undervalued while ongoing
North Carolina leaders praise a $590 million settlement between Chemours, DuPont, and Corteva regarding PFAS contamination. However, local well owners remain skeptical about the deal's ability to prov
Chemours faces a new class-action lawsuit from Wood County residents alleging PFAS contamination from its Washington Works landfill caused property damage and health issues. The plaintiffs seek cleanu
Chemours released its 2025 Sustainability Report, highlighting an 80% reduction in fluorinated organic compound emissions since 2018 and a 57% drop in production greenhouse gases toward 2030 targets.
Chemours stock held near $14.70 despite a $274 million Q2 loss and ongoing PFAS litigation risks, including a $455 million settlement with North Carolina, while revenue rose to $1.59 billion.
Bladen County secures $26.6 million from DuPont and Chemours to upgrade water infrastructure following a PFAS pollution settlement tied to their Fayetteville Works plant, part of a larger $590 million
Chemours reported mixed Q2 results with trimmed net losses and improved cash flow despite flat net sales due to volume declines. Future performance hinges on pricing gains offsetting shrinking demand
Chemours has reached a nearly $600 million settlement with North Carolina to provide clean drinking water for PFAS contamination. Backed by DuPont, the agreement ensures funds for local governments de
A federal judge ruled Chemours liable for illegally dumping forever chemicals into the Cape Fear River since 1980, impacting over 180,000 residents. A jury trial is set for next March to determine com
Chemours released its 2025 Sustainability Report, highlighting an 80% reduction in fluorinated organic chemical emissions and a 57% cut in greenhouse gases since 2018. The company also reported zero m
Zacks Research downgraded Chemours to 'Strong Sell' following missed quarterly earnings estimates for EPS and revenue. Analyst consensus remains Hold with a $21 price target despite the recent downgra
Chemours Co CFO Shane Hostetter bought 3,350 shares at $14.94, boosting direct ownership to over 102,000 shares. This transaction signals insider confidence while the stock remains modestly undervalue
Chemours Co CFO Shane Hostetter acquired 3,350 shares at $14.94 per share on August 6, increasing his beneficial ownership to 102,697 shares.
Analysts reduced Chemours' 12-month price target to $22.5 from $22.8, maintaining a consensus Buy rating from 11 analysts.
Chemours Co trades ex-dividend with a 2.2% yield, but analysts warn of risks due to last year's loss and declining five-year earnings. Despite free cash flow coverage, dividend sustainability remains
Chemours Q2 sales fell 1% to $1.591 billion amid lower Opteon refrigerant demand, though adjusted net profit reached $64 million meeting analyst expectations with free cash flow up 128%.
First Trust Advisors LP reduced its Chemours stake by 45.7% after the company missed Q2 earnings, causing an 18.3% stock drop. Analysts retain a Moderate Buy rating despite litigation costs.
Analysts lowered Chemours' 12-month price target to $24.9, implying 39% upside from current prices. The consensus rating remains 'Buy' despite the slight reduction.
Chemours maintained its 2026 outlook despite lower aftermarket refrigerant sales, reporting flat Q2 net sales of $1.591 billion. Adjusted EBITDA in its Thermal & Specialized Solutions segment rose 3%,
Chemours shares dropped 13% following a narrower loss and weak Q3 outlook driven by refrigerant demand weakness. Management anticipates titanium dioxide pricing improvements to mitigate ongoing litiga
Chemours anticipates improved Q2 earnings with $1.66 billion revenue, while investors monitor the impact of its $450 million PFAS settlement and titanium dioxide trends. Despite a Buy rating, analysts
North Carolina officials oppose a $450 million EPA settlement with Chemours over PFAS pollution in the Cape Fear River. Leaders demand a fairer deal addressing cleanup needs and resident benefits.
North Carolina officials criticize a $450 million EPA-Chemours PFAS settlement, claiming it excludes state input and inadequately addresses local damage. They urge the federal government to withdraw t
North Carolina officials oppose a federal settlement with Chemours, claiming it inadequately addresses PFAS pollution and allows the company to evade accountability. They have filed supporting documen
Chemours Co maintains a 'Hold' rating from analysts, with a top price target of $25 implying 45% upside potential. The company demonstrates stable fundamentals and high institutional ownership despite
Over 2,600 North Carolina residents settled with Chemours and DuPont over PFAS groundwater contamination from the 1980s. Broader litigation and filtration issues remain unresolved in the region.
A federal settlement imposes strict oversight and a $22.5 million penalty on Chemours' Fayetteville Works plant to address PFAS contamination. While national funding exceeds $450 million, local offici
Chemours received broker upgrades and a Zacks Rank #1 status driven by stronger earnings growth forecasts through 2026. Investors must weigh this sentiment against significant environmental risks, inc
A proposed federal settlement regarding Chemours' Fayetteville Works plant has raised local concerns over PFAS contamination and water quality funding. While pollution controls are included, direct fi
Over 2,600 residents settled a PFAS contamination lawsuit against Chemours and DuPont regarding groundwater pollution dating back to the 1980s. The agreement precedes a key trial, though maintenance d
Chemours stock has declined recently despite year-to-date gains, with analysts valuing shares at $30 against a current price of $18.24. The company faces headwinds from PFAS litigation and competition
Chemours agreed to a $450 million settlement with federal and state agencies over PFAS river contamination, despite criticism that the deal allows continued manufacturing of the chemicals.
A North Carolina plaintiff waited eight years for a PFAS trial against Chemours and DuPont, only to learn the case involving 2,658 plaintiffs over Fayetteville Works plant contamination was settled ou
ChemBrief